

Luis E Rohde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5533731/publications.pdf>

Version: 2024-02-01

57
papers

2,040
citations

394421

19
h-index

243625

44
g-index

60
all docs

60
docs citations

60
times ranked

3654
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in <sc>PARADIGM-HF</sc>. European Journal of Heart Failure, 2022, 24, 551-561.	7.1	20
2	Reduction of dietary sodium for heart failure: a step forward. Lancet, The, 2022, 399, 1361-1363.	13.7	0
3	Is There Room for Sacubitril-Valsartan in the Treatment of Advanced Heart Failure?. , 2022, 2, 192-194.		0
4	Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II. Heart, 2021, 107, 1487-1492.	2.9	8
5	Why do poor patients have poor outcomes? Shedding light on the neglected facet of poverty and heart failure. Heart, 2021, 107, 178-179.	2.9	1
6	GDF-15 como Biomarcador em DoenÇas Cardiovasculares. Arquivos Brasileiros De Cardiologia, 2021, 116, 494-500.	0.8	13
7	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	3.9	13
8	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <sc>PARADIGM-HF</sc> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	7.1	11
9	Effects of a diuretic adjustment algorithm protocol on heart failure admissions: A randomized clinical trial. Journal of Telemedicine and Telecare, 2021, 27, 288-297.	2.7	0
10	Preditores de Mortalidade Total e Eventos Arritmicos Graves em Pacientes com InsuficiÃncia CardÃaca NÃo IsquÃmica: O Papel da Galectina-3. Arquivos Brasileiros De Cardiologia, 2021, 117, 531-541.	0.8	6
11	Posicionamento sobre DiagnÃstico e Tratamento da Amiloidose CardÃaca â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 561-598.	0.8	35
12	AtualizaÃÃo de TÃpicos Emergentes da Diretriz Brasileira de InsuficiÃncia CardÃaca â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 116, 1174-1212.	0.8	13
13	Growth/differentiation factor-15 (GDF-15) as a predictor of serious arrhythmic events in patients with nonischemic dilated cardiomyopathy. Journal of Electrocardiology, 2021, 70, 19-23.	0.9	5
14	Algorithms for Cardiac Amyloidosis Diagnosis: How to apply them in practice?. , 2021, 1, 139-143.		0
15	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. JACC: Heart Failure, 2020, 8, 844-855.	4.1	56
16	COVID-19 in Brazil: the headlines should be about science. Lancet, The, 2020, 396, 1803.	13.7	4
17	Association between serum lactate levels and mortality in patients with cardiogenic shock receiving mechanical circulatory support: a multicenter retrospective cohort study. BMC Cardiovascular Disorders, 2020, 20, 496.	1.7	22
18	Identification of environmental and genetic factors that influence warfarin time in therapeutic range. Genetics and Molecular Biology, 2020, 43, e20190025.	1.3	3

#	ARTICLE	IF	CITATIONS
19	TÃ³picos Emergentes em InsuficiÃªncia CardÃaca: Perspectivas Futuras. Arquivos Brasileiros De Cardiologia, 2020, 115, 1197-1200.	0.8	0
20	Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. European Heart Journal, 2019, 40, 3605-3612.	2.2	46
21	Characterization of advanced glycation end products and their receptor (RAGE) in an animal model of myocardial infarction. PLoS ONE, 2019, 14, e0209964.	2.5	5
22	The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant. Arquivos Brasileiros De Cardiologia, 2019, 112, 791-792.	0.8	0
23	Alcohol and the heart: the good, the bad and the worse in heart failure. Heart, 2018, 104, 1641-1642.	2.9	5
24	Aggressive fluid and sodium restriction in decompensated heart failure with preserved ejection fraction: Results from a randomized clinical trial. Nutrition, 2018, 54, 111-117.	2.4	24
25	Plasma levels of microRNA-21, -126 and -423-5p alter during clinical improvement and are associated with the prognosis of acute heart failure. Molecular Medicine Reports, 2018, 17, 4736-4746.	2.4	24
26	Relationship of polymorphisms in the tissue inhibitor of metalloproteinase (TIMP)-1 and -2 genes with chronic heart failure. Scientific Reports, 2018, 8, 9446.	3.3	7
27	Cost-Effectiveness of a Home Visit Program for Patients with Heart Failure in Brazil: Evidence from a Randomized Clinical Trial. Value in Health Regional Issues, 2018, 17, 81-87.	1.2	7
28	Vaccinations in Heart Failure. JACC: Heart Failure, 2018, 6, 856-858.	4.1	0
29	The tip of the iceberg in the sub-Saharan Africa: unraveling the real world in the diagnosis and treatment of heart failure. Heart, 2017, 103, 1842-1843.	2.9	1
30	Predictors of serious arrhythmic events in patients with nonischemic heart failure. Journal of Interventional Cardiac Electrophysiology, 2017, 48, 131-139.	1.3	8
31	Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial. American Heart Journal, 2017, 194, 125-131.	2.7	8
32	Matrix Metalloproteinase-2 Polymorphisms in Chronic Heart Failure: Relationship with Susceptibility and Long-Term Survival. PLoS ONE, 2016, 11, e0161666.	2.5	13
33	Long-term Cost-effectiveness of Diagnostic Tests for Assessing Stable Chest Pain: Modeled Analysis of Anatomical and Functional Strategies. Clinical Cardiology, 2016, 39, 249-256.	1.8	20
34	Short-term Effects of High-Dose Caffeine on Cardiac Arrhythmias in Patients With Heart Failure. JAMA Internal Medicine, 2016, 176, 1752.	5.1	28
35	Effect of caffeine on ventricular arrhythmia: a systematic review and meta-analysis of experimental and clinical studies. Europace, 2016, 18, 257-266.	1.7	33
36	Sudden cardiac death markers in non-ischemic cardiomyopathy. Journal of Electrocardiology, 2016, 49, 446-451.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Circulating microRNAs in obese and lean heart failure patients: A case-control study with computational target prediction analysis. <i>Gene</i> , 2015, 574, 1-10.	2.2	21
38	N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperused Acute Myocardial Infarction. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 328-337.	2.4	4
39	Tumorlike Cardiac Fungal Mycetoma Caused by <i>Scedosporium apiospermum</i> Presenting as Symptomatic Ventricular Tachycardia. <i>Circulation</i> , 2014, 129, e488-9.	1.6	0
40	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, 4-25.	3.1	921
41	Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 338-344.	2.1	8
42	Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability. <i>Biomarkers</i> , 2014, 19, 49-55.	1.9	61
43	Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression. <i>Biomarkers</i> , 2014, 19, 135-141.	1.9	43
44	QRS Widening Rates and Genetic Polymorphisms of Matrix Metalloproteinases in a Cohort of Patients With Chronic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 345-351.	1.7	7
45	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	3.1	5
46	An Analysis of the Global Expression of MicroRNAs in an Experimental Model of Physiological Left Ventricular Hypertrophy. <i>PLoS ONE</i> , 2014, 9, e93271.	2.5	53
47	Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health system. <i>International Journal of Cardiology</i> , 2013, 163, 309-315.	1.7	27
48	IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia. <i>International Journal of Cardiology</i> , 2013, 168, 3439-3442.	1.7	192
49	Cost-effectiveness of heart failure therapies. <i>Nature Reviews Cardiology</i> , 2013, 10, 338-354.	13.7	66
50	Nurses' performance in classifying heart failure patients based on physical exam: comparison with cardiologists' physical exam and levels of N-terminal pro-B-type natriuretic peptide. <i>Journal of Clinical Nursing</i> , 2010, 19, 3381-3389.	3.0	21
51	Dietary vitamin K intake and anticoagulation in elderly patients. <i>Current Opinion in Internal Medicine</i> , 2007, 6, 120-124.	1.5	23
52	A Hemodynamically Oriented Echocardiography-Based Strategy in the Treatment of Congestive Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 618-625.	1.7	42
53	Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. <i>International Journal of Cardiovascular Imaging</i> , 2007, 23, 185-191.	1.5	12
54	Superoxide Dismutase Activity in Adriamycin-Induced Cardiotoxicity in Humans: A Potential Novel Tool for Risk Stratification. <i>Journal of Cardiac Failure</i> , 2005, 11, 220-226.	1.7	12

#	ARTICLE	IF	CITATIONS
55	Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Canadian Journal of Cardiology, 2004, 20, 697-702.	1.7	57
56	Implications of the Hemodynamic Optimization Approach Guided by Right Heart Catheterization in Patients with Severe Heart Failure. Arquivos Brasileiros De Cardiologia, 2002, 78, 261-266.	0.8	7
57	Doses altas versus baixas de inibidores da eca em insuficiÃªncia cardÃaca. , 0, , .		0